Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

EnVivo gets license to MethylGene's HDAC inhibitors

Executive Summary

EnVivo Pharmaceuticals (CNS disorders) has exercised its option to exclusively use MethylGene's (cancer and infectious diseases) isotypic selective small-molecule histone deacetylase (HDAC) inhibitors to create therapeutics for neurodegenerative diseases including Alzheimer's, Parkinson's, and Huntington's.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing

Related Companies